<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/112248">
      <dc:title>Biosimilar eculizumab and meningococcal meningitis: the importance of strengthening health education</dc:title>
      <dc:creator>Fernández-Varela, Alba María</dc:creator>
      <dc:creator>Villaverde Piñeiro, Laura</dc:creator>
      <dc:creator>Álvarez Payero, Miriam</dc:creator>
      <dc:description>This manuscript addresses the development of meningitis associated with biosimilar Eculizumab in paroxysmal nocturnal hemoglobinuria (PNH), emphasizing the importance of health education provided by healthcare professionals for the early detection of meningitis, as well as the relevance of updating vaccination schedules. There are no published reports in the literature on meningitis caused by biosimilar Eculizumab (Bekemv®), a drug marketed in April 2023. The importance of reporting adverse drug reactions (ADRs) to pharmacovigilance systems is highlighted, which contributes to expanding the safety profile of the drug.</dc:description>
      <dc:description>El manuscrito aborda el desarrollo de meningitis asociada a  Eculizumab biosimilar en  hemoglobinuria paroxística nocturna (HPN), enfatizando la importancia de la educación sanitaria proporcionada por los profesionales de la salud para la detección temprana de la meningitis, así como la relevancia de actualizar los calendarios de vacunación. No existen informes publicados en la literatura sobre meningitis causada por Eculizumab biosimilar (Bekemv®), un medicamento comercializado en abril de 2023. Se destaca la importancia de notificar las reacciones adversas a medicamentos (RAM) a los sistemas de farmacovigilancia, lo que contribuye a ampliar el perfil de seguridad del fármaco.</dc:description>
      <dc:date>2026-03-18T13:05:28Z</dc:date>
      <dc:date>2026-03-18T13:05:28Z</dc:date>
      <dc:date>2025-12-20</dc:date>
      <dc:type>journal article</dc:type>
      <dc:identifier>Fernández Varela AM, Villaverde Piñeiro L, Álvarez Payero M. Biosimilar eculizumab and meningococcal meningitis: the importance of strengthening health education. Ars Pharm [Internet]. 2025 Dec. 20 [cited 2026 Mar. 18];67(1):6-8. Available from: https://revistaseug.ugr.es/index.php/ars/article/view/34997Fernández Varela AM, Villaverde Piñeiro L, Álvarez Payero M. Biosimilar eculizumab and meningococcal meningitis: the importance of strengthening health education. Ars Pharm [Internet]. 2025 Dec. 20 [cited 2026 Mar. 18];67(1):6-8. Available from: https://revistaseug.ugr.es/index.php/ars/article/view/34997. https://doi.org/10.30827/ars.v67i1.34997</dc:identifier>
      <dc:identifier>2340-9894</dc:identifier>
      <dc:identifier>https://hdl.handle.net/10481/112248</dc:identifier>
      <dc:identifier>10.30827/ars.v67i1.34997</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by-nc-sa/4.0/</dc:rights>
      <dc:rights>open access</dc:rights>
      <dc:rights>Atribución-NoComercial-CompartirIgual 4.0 Internacional</dc:rights>
      <dc:publisher>Universidad de Granada</dc:publisher>
   </ow:Publication>
</rdf:RDF>